From Investing.com: 2024-04-03 10:22:26

Lenz Therapeutics’ experimental drug for presbyopia, LNZ100, showed promising results in a late-stage study, improving nearsightedness without affecting distant vision. Shares of the company rose 4.2% to $21.89. The drug, if approved, could offer a new treatment option for the estimated 128 million Americans affected by the eye disorder.

The two six-week efficacy trials and a six-month safety trial for Lenz’s eye drop included 1,059 participants aged 45 to 75. 71% of patients experienced improved near vision without affecting their ability to see things far away, three hours post-treatment. The company plans to submit a U.S. marketing application for LNZ100 by mid-2024.

In the competitive landscape, Abbvie’s Vuity is the first FDA-approved eye drop for presbyopia. Rival companies Eyenovia and Ocuphire Pharma are also developing treatments for the condition, with late-stage trials underway for Eyenovia’s Optejet device and Ocuphire’s eye drop. Lenz’s drug, LNZ101, showed promising results but did not demonstrate superiority to LNZ100.



Read more at Investing.com: Lenz Therapeutics’ eye drop helps improve vision in late-stage study By Reuters